Daré Bioscience, Inc.
DARE
$2.93
-$0.055-1.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -252.52% | 86.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -252.52% | 86.16% | |||
| Cost of Revenue | 56,790.00% | 0.00% | |||
| Gross Profit | -85,646.11% | 742.31% | |||
| SG&A Expenses | -2.21% | -16.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.74% | -36.02% | |||
| Operating Income | -15.10% | 36.39% | |||
| Income Before Tax | -17.10% | -136.42% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -17.10% | -136.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -17.10% | -136.42% | |||
| EBIT | -15.10% | 36.39% | |||
| EBITDA | -15.20% | 36.39% | |||
| EPS Basic | -24.61% | -135.90% | |||
| Normalized Basic EPS | -38.18% | -135.90% | |||
| EPS Diluted | -25.15% | -136.25% | |||
| Normalized Diluted EPS | -38.18% | -136.18% | |||
| Average Basic Shares Outstanding | -6.04% | 1.46% | |||
| Average Diluted Shares Outstanding | -6.04% | 0.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||